ClinicalTrials.gg
CompletedNCT00871949Updated Aug 27, 2013

Safety, Tolerability And Pharmacokinetics Study Of Single Doses Of PNU-100480 In Healthy Adults

A Phase 1 interventional study of PNU-100480 and PNU-100480 in Tuberculosis, sponsored by Sequella, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-08-27.

Sponsored by Sequella, Inc. · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 129 studies in Tuberculosis with a site in United States — 4 open to participants now, 4 under way, none of them phase 3. Tuberculosis · United States.

Enrollment
76th of 94
19 · median 56
Started
2009
with 5 others
Phase 1
44 of 129
1 open now
Registered
48th of 129
by date
Lead sponsor
3 of 129
Sequella, Inc.

Among the 129 studies in Tuberculosis with a site in United States, this one is the 76th largest by enrollment of the 94 interventional ones that give a count, is one of 6 that started in 2009, is one of 44 in phase 1, and was the 48th registered.

Tuberculosis

1,170 studies on the registry are indexed under Tuberculosis; 175 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

4 of the 129 studies in Tuberculosis with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 111 Tuberculosis studies recruiting now, 65 (59%) set no upper age limit and 36 (32%) stop at 75 or younger; 48 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Tuberculosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of PNU-100480 (PF-02341272) after a single dose in healthy adult volunteers.

03

Conditions studied

  • Tuberculosis

Browse trials for

Keywords

  • Safety tolerability pharmacokinetics PK first in human FIH
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult volunteers willing and able to be confined to the Clinical Research Unit and comply with study schedule.
  • Women of non- only.

Exclusion criteria

Exclusion Criteria:

  • History of to, or intolerance of, linezolid.
  • Antibiotic treatment within 14 days prior to dosing.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Cohort 1, Sequence 1

    Period 1- Placebo Period 2- 100 mg Period 3- 300 mg

    Drug: PNU-100480 · Drug: Placebo

  • Experimental
    Cohort 1, Sequence 2

    Period 1- 35 mg Period 2- Placebo Period 3- 300 mg

    Drug: PNU-100480 · Drug: Placebo

  • Experimental
    Cohort 1, Sequence 3

    Period 1- 35 mg Period 2- 100 mg Period 3- Placebo

    Drug: PNU-100480 · Drug: Placebo

  • Experimental
    Cohort 2, Sequence 1

    Period 1- Placebo Period 2- 1000 mg Period 3- 1500 mg Period 4- 600 mg (Fed conditions)

    Drug: PNU-100480 · Drug: Placebo

  • Experimental
    Cohort 2, Sequence 2

    Period 1- 600 mg Period 2- Placebo Period 3- 1500 mg Period 4- 600 mg (Fed conditions)

    Drug: PNU-100480 · Drug: Placebo

  • Experimental
    Cohort 2, Sequence 3

    Period 1- 600 mg Period 2- 1000 mg Period 3- Placebo Period 4- 600 mg (Fed conditions)

    Drug: PNU-100480 · Drug: Placebo

Interventions

  • 100 mg oral suspension given once

    Also known as: Period 2

  • 300 mg oral suspension given once

    Also known as: Period 3

  • DrugPlacebo

    placebo to match oral suspension given once

    Also known as: Period 1

  • 300 mg oral suspension given once

    Also known as: Period 3

  • 35 mg oral suspension given once

    Also known as: Period 1

  • DrugPlacebo

    placebo to match oral suspension given once

    Also known as: Period 2

  • 100 mg oral suspension given once

    Also known as: Period 2

  • 35 mg oral suspension given once

    Also known as: Period 1

  • DrugPlacebo

    placebo to match oral suspension given once

    Also known as: Period 3

  • 1000 mg oral suspension given once

    Also known as: Period 2

  • 1500 mg oral suspension given once

    Also known as: Period 3

  • Fed conditions, 600 mg oral suspension given once

    Also known as: Period 4 (Fed)

  • DrugPlacebo

    placebo to match oral suspension given once

    Also known as: Period 1

  • 1500 mg oral suspension given once

    Also known as: Period 3

  • 600 mg oral suspension given once

    Also known as: Period 1

  • Fed conditions, 600 mg oral suspension given once

    Also known as: Period 4 (Fed)

  • DrugPlacebo

    placebo to match oral suspension given once

    Also known as: Period 2

  • 1000 mg oral suspension given once

    Also known as: Period 2

  • 600 mg oral suspension given once

    Also known as: Period 1

  • Fed conditions, 600 mg oral suspension given once

    Also known as: Period 4 (Fed)

  • DrugPlacebo

    placebo to match oral suspension given once

    Also known as: Period 3

06

What researchers measure

Primary outcomes

  1. Evaluation of safety and tolerability of escalating single oral doses of PNU-100480.

    Time frame: Daily, Days 1-3 or 4, and 7-14 days after dosing.

Secondary outcomes

  1. Characterize pharmacokinetics of single oral doses PNU-100480.

    Time frame: Predose; multiple timepoints postdose on Day 1, and up to 72 hours postdose.

  2. Characterize the effect of food on the pharmacokinetics of a single oral dose of PNU-100480.

    Time frame: Predose; multiple timepoints postdose on Day 1, and up to 72 hours postdose.

  3. Characterize the bactericidal activity in blood of orally administered PNU-100480 against intracellular Mycobacterium tuberculosis in relation to blood concentrations of PNU-100480 (and its metabolites) (some periods only)

    Time frame: Predose and timpoints up to 24 hours post dose on Day 1 (only in some periods)

07

Study locations

1 site
  • Pfizer Investigational Site
    New Haven, Connecticut 06511, United States
08

References and documents

Publications

  • Wallis RS, Jakubiec WM, Kumar V, Silvia AM, Paige D, Dimitrova D, Li X, Ladutko L, Campbell S, Friedland G, Mitton-Fry M, Miller PF. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J Infect Dis. 2010 Sep 1;202(5):745-51. doi: 10.1086/655471. PubMed 20629533 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Aug 2009 and a completion of Aug 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2009
First posted
Mar 30, 2009
Start
Apr 2009
Primary completionActual
Aug 2009
CompletionActual
Aug 2009
Last update
Aug 27, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00871949
Lead sponsor
Sequella, Inc.
Responsible party
Sponsor
First posted
Mar 30, 2009
Start date
Apr 2009
Primary completion
Aug 2009
Completion
Aug 2009
Last update
Aug 27, 2013

Study contacts

Lisa Beth Ferstenberg, M.D.
study director · Sequella, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PNU-100480

Start the discussion